Transcode Therapeutics, Inc. (RNAZ) — Institutional Holders, Q2 2026
8 institutional investment managers reported a RNAZ position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $208.1K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
RNAZ in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- Yorkville Advisors GlobalNew · +19,639 sh+$122.0K
- FMRNew · +706 sh+$4.4K
- Tower Research Capital (TRC)Added · +449 sh+$2.8K
Biggest sellers
- GEODE CAPITAL MANAGEMENTSold out · -12,740 sh-$79.1K
- UBS Group AGTrimmed · -5,407 sh-$33.6K
RNAZ 13F holders ranked 1–8 of 8
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | Yorkville Advisors Global#1 · 19,639 sh | 19,639 | $122.0K | 0.14% | New |
| 2 | VANGUARD CAPITAL MANAGEMENT#2 · 6,545 sh | 6,545 | $40.6K | 0.00% | 0.0% |
| 3 | VANGUARD FIDUCIARY#3 · 2,982 sh | 2,982 | $18.5K | 0.00% | 0.0% |
| 4 | UBS Group AG#4 · 2,888 sh | 2,888 | $17.9K | 0.00% | -65.2% |
| 5 | FMR#5 · 706 sh | 706 | $4.4K | 0.00% | New |
| 6 | Tower Research Capital (TRC)#6 · 677 sh | 677 | $4.2K | <0.01% | +196.9% |
| 7 | WELLS FARGO & COMPANY#7 · 55 sh | 55 | $342.00 | 0.00% | 0.0% |
| 8 | SBI Securities , Ltd.#8 · 12 sh | 12 | $75.00 | — | 0.0% |
Funds that sold out of RNAZ in Q2 2026 (2)
Held RNAZ at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| GEODE CAPITAL MANAGEMENT12,740 sh | 12,740 | $109.7K |
| ROYAL BANK OF CANADA8 sh | 8 | $0.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.